Kim De Keersmaecker

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5946800/publications.pdf

Version: 2024-02-01

94 papers	4,927 citations	87888 38 h-index	95266 68 g-index
98 all docs	98 docs citations	98 times ranked	7755 citing authors

#	Article	IF	Citations
1	Exploitation of the ribosomal protein L10 R98S mutation to enhance recombinant protein production in mammalian cells. Engineering in Life Sciences, 2022, 22, 100-114.	3.6	0
2	HEATR3 variants impair nuclear import of uL18 (RPL5) and drive Diamond-Blackfan anemia. Blood, 2022, 139, 3111-3126.	1.4	15
3	Monitoring of Leukemia Clones in B-cell Acute Lymphoblastic Leukemia at Diagnosis and During Treatment by Single-cell DNA Amplicon Sequencing. HemaSphere, 2022, 6, e700.	2.7	8
4	Single-cell DNA amplicon sequencing reveals clonal heterogeneity and evolution in T-cell acute lymphoblastic leukemia. Blood, 2021, 137, 801-811.	1.4	43
5	Codon bias analyses on thyroid carcinoma genes. Minerva Endocrinologica, 2021, 45, 295-305.	1.8	10
6	14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T and myeloid immature acute leukemia. Blood, 2021, 138, 773-784.	1.4	19
7	PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemia. Journal of Hematology and Oncology, 2021, 14, 97.	17.0	10
8	The ins and outs of serine and glycine metabolism in cancer. Nature Metabolism, 2021, 3, 131-141.	11.9	82
9	Repurposing the Antidepressant Sertraline as SHMT Inhibitor to Suppress Serine/Glycine Synthesisâ€“Addicted Breast Tumor Growth. Molecular Cancer Therapeutics, 2021, 20, 50-63.	4.1	31
10	Loss of the Base Excision Repair Gene Apex1 Leads to Dysfunctional Adult Hematopoietic Stem and Progenitor Cells. Blood, 2021, 138, 3267-3267.	1.4	0
11	Hallmarks of ribosomopathies. Nucleic Acids Research, 2020, 48, 1013-1028.	14.5	122
12	Carfilzomib-induced reticulocytosis in patients with multiple myeloma is caused by impaired terminal erythroid maturation. Leukemia, 2020, 34, 651-655.	7.2	0
13	The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia. Clinical Cancer Research, 2020, 26, 5747-5758.	7.0	19
14	SAMHD1 Limits the Efficacy of Forodesine in Leukemia by Protecting Cells against the Cytotoxicity of dGTP. Cell Reports, 2020, 31, 107640.	6.4	16
15	Abstract 1789: Repurposing the anti-depressant sertraline to target serine/glycine synthesis addicted cancer. , 2020, , .		0
16	Opportunities of Genome Imaging for Genetic Diagnosis in Acute Lymphoblastic Leukemia. Blood, 2020, 136, 10-11.	1.4	0
17	The ribosomal RPL10 R98S mutation drives IRES-dependent BCL-2 translation in T-ALL. Leukemia, 2019, 33, 319-332.	7.2	50
18	Translatome analysis reveals altered serine and glycine metabolism in T-cell acute lymphoblastic leukemia cells. Nature Communications, 2019, 10, 2542.	12.8	43

#	Article	IF	Citations
19	Cancer Biogenesis in Ribosomopathies. Cells, 2019, 8, 229.	4.1	64
20	Large expert-curated database for benchmarking document similarity detection in biomedical literature search. Database: the Journal of Biological Databases and Curation, 2019, 2019, .	3.0	15
21	PF165 THE XPO1 INHIBITOR KPTâ€8602 WORKS SYNERGISTIC WITH DEXAMETHASONE TO INHIBIT ACUTE LYMPHOBLASTIC LEUKEMIA CELLS. HemaSphere, 2019, 3, 34-35.	2.7	0
22	PF159 COMBINATION OF SELECTIVE GAMMAâ€SECRETASE INHIBITOR MRKâ€560 WITH OTHER TARGETED THERAPY IS AN EFFECTIVE AND SAFE TREATMENT FOR Tâ€ALL. HemaSphere, 2019, 3, 31.	2.7	0
23	Ruxolitinib Synergizes With Dexamethasone for the Treatment of T-cell Acute Lymphoblastic Leukemia. HemaSphere, 2019, 3, e310.	2.7	19
24	Ribosomal Lesions Promote Oncogenic Mutagenesis. Cancer Research, 2019, 79, 320-327.	0.9	22
25	PF570 CARFILZOMIB TREATMENT CAUSES RETICULOCYTOSIS BY IMPAIRING TERMINAL ERYTHROID MATURATION IN PATIENTS WITH MULTIPLE MYELOMA. HemaSphere, 2019, 3, 237.	2.7	0
26	Evolution of Clinically Relevant Subclones during Chemotherapy Treatment of ALL As Determined By Single-Cell DNA and RNA Sequencing. Blood, 2019, 134, 2749-2749.	1.4	0
27	The T-cell leukemia-associated ribosomal RPL10 R98S mutation enhances JAK-STAT signaling. Leukemia, 2018, 32, 809-819.	7.2	57
28	Analysis of Gene Expression Data of RPL10 Mutant T-Cell Leukemia by SEMsubPA. , 2018, , .		0
29	Bloody Mysteries of Ribosomes. HemaSphere, 2018, 2, e95.	2.7	5
30	VEGFC Antibody Therapy Drives Differentiation of AML. Cancer Research, 2018, 78, 5940-5948.	0.9	12
31	EML1â€“ABL1 Is Activated by Coiledâ€Coilâ€Mediated Oligomerization and Induces Tâ€Cell Acute Lymphoblastic Leukemia or Myeloproliferative Disease in a Mouse Bone Marrow Transplant Model. HemaSphere, 2018, 2, e32.	2.7	2
32	Single-cell sequencing reveals the origin and the order of mutation acquisition in T-cell acute lymphoblastic leukemia. Leukemia, 2018, 32, 1358-1369.	7.2	66
33	Rise of the specialized onco-ribosomes. Oncotarget, 2018, 9, 35205-35206.	1.8	7
34	Proteasome Inhibition By Carfilzomib Impairs Terminal Erythroid Maturation and Causes Reticulocytosis in Patients with Multiple Myeloma. Blood, 2018, 132, 1036-1036.	1.4	0
35	The genetics and molecular biology of T-ALL. Blood, 2017, 129, 1113-1123.	1.4	273
36	Synergistic antileukemic therapies in NOTCH1 -induced T-ALL. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 2006-2011.	7.1	50

#	Article	IF	Citations
37	Low frequency mutations in ribosomal proteins RPL10 and RPL5 in multiple myeloma. Haematologica, 2017, 102, e317-e320.	3.5	27
38	RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response. Leukemia, 2017, 31, 1706-1714.	7.2	49
39	How Ribosomes Translate Cancer. Cancer Discovery, 2017, 7, 1069-1087.	9.4	131
40	The ribosomal protein gene RPL5 is a haploinsufficient tumor suppressor in multiple cancer types. Oncotarget, 2017, 8, 14462-14478.	1.8	92
41	Ribosomal proteins: a novel class of oncogenic drivers. Oncotarget, 2017, 8, 89427-89428.	1.8	8
42	Abstract 1546: Contribution of heterozygous loss of ribosomal protein L5 as general tumor suppressor in cancer. , 2017, , .		0
43	Abstract 3034: A programmed ribosomal frameshifting defect potentiates the transforming activity of the JAK2-V617F mutation. , 2017, , .		0
44	Ribosomal <scp>RNA</scp> analysis in the diagnosis of Diamondâ€Blackfan Anaemia. British Journal of Haematology, 2016, 172, 782-785.	2.5	24
45	Ribosomopathies and the paradox of cellular hypo- to hyperproliferation. Blood, 2015, 125, 1377-1382.	1.4	83
46	A novel mouse model provides insights into the neutropenia associated with the ribosomopathy Shwachman-Diamond syndrome. Haematologica, 2015, 100, 1237-1239.	3.5	4
47	T-ALL: ALL a matter of Translation?. Haematologica, 2015, 100, 293-295.	3.5	8
48	RPL5 Is a Candidate Tumor Suppressor on 1p22.1 in Multiple Myeloma of Which the Expression Is Linked to Bortezomib Response. Blood, 2015, 126, 2969-2969.	1.4	0
49	Synergistic Targeting of Protein Translation and Inhibition of NOTCH Signaling in T-ALL. Blood, 2015, 126, 3719-3719.	1.4	0
50	Bypass of the pre-60S ribosomal quality control as a pathway to oncogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 5640-5645.	7.1	71
51	NUP214-ABL1-mediated cell proliferation in T-cell acute lymphoblastic leukemia is dependent on the LCK kinase and various interacting proteins. Haematologica, 2014, 99, 85-93.	3.5	38
52	Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia. Nature Genetics, 2013, 45, 186-190.	21.4	365
53	Comprehensive Analysis of Transcriptome Variation Uncovers Known and Novel Driver Events in T-Cell Acute Lymphoblastic Leukemia. PLoS Genetics, 2013, 9, e1003997.	3.5	110
54	Prognostic relevance of integrated genetic profiling in adult T-cell acute lymphoblastic leukemia. Blood, 2013, 122, 74-82.	1.4	133

#	Article	IF	Citations
55	Whole Transcriptome Sequencing In Refractory T-Cell Acute Lymphoblastic Leukemia. Blood, 2013, 122, 350-350.	1.4	0
56	Novel insights on TLX1 function in T-ALL pave the way towards differentiation therapy. Haematologica, 2012, 97, 795-795.	3.5	0
57	The other Achilles' heel of BCR-ABL1. Haematologica, 2012, 97, 2-2.	3.5	4
58	Rearrangement of NOTCH1 or BCL3 can independently trigger progression of CLL. Blood, 2012, 119, 3864-3866.	1.4	12
59	An activating intragenic deletion in NOTCH1 in human T-ALL. Blood, 2012, 119, 5211-5214.	1.4	22
60	Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nature Medicine, 2012, 18, 298-302.	30.7	453
61	Reverse engineering of TLX oncogenic transcriptional networks identifies RUNX1 as tumor suppressor in T-ALL. Nature Medicine, 2012, 18, 436-440.	30.7	138
62	Mutation of the receptor tyrosine phosphatase PTPRC (CD45) in T-cell acute lymphoblastic leukemia. Blood, 2012, 119, 4476-4479.	1.4	96
63	Targeting Nonclassical Oncogenes for Therapy in T-ALL. Cancer Cell, 2012, 21, 459-472.	16.8	84
64	High Accuracy Mutation Detection in Leukemia on a Selected Panel of Cancer Genes. PLoS ONE, 2012, 7, e38463.	2.5	58
65	Therapeutic Utility of PI3KÎ³ Inhibition in Leukemogenesis and Tumor Cell Survival. Blood, 2012, 120, 1492-1492.	1.4	1
66	Loss or Inhibition of Stromal-Derived PlGF Prolongs Survival of Mice with Imatinib-Resistant Bcr-Abl1+ Leukemia. Cancer Cell, 2011, 19, 740-753.	16.8	124
67	TLX1-Induced T-cell Acute Lymphoblastic Leukemia. Clinical Cancer Research, 2011, 17, 6381-6386.	7.0	14
68	Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia. Nature Cell Biology, 2010, 12, 372-379.	10.3	316
69	Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia. Nature Genetics, 2010, 42, 530-535.	21.4	162
70	Deletion of the RNA-binding proteins ZFP36L1 and ZFP36L2 leads to perturbed thymic development and T lymphoblastic leukemia. Nature Immunology, 2010, 11, 717-724.	14.5	187
71	The TLX1 oncogene drives aneuploidy in T cell transformation. Nature Medicine, 2010, 16, 1321-1327.	30.7	139
72	Precursor T-Cell Neoplasms. Molecular Pathology Library, 2010, , 329-346.	0.1	0

#	Article	IF	Citations
73	BCL11B Mutations In T-Cell Acute Lymphoblastic Leukemia. Blood, 2010, 116, 471-471.	1.4	0
74	T-Cell acute lymphoblastic leukemia with a â€œpinchâ€•of BCR-ABL1. Leukemia and Lymphoma, 2009, 50, 321-322.	1.3	1
75	Heterogeneous patterns of amplification of the NUP214-ABL1 fusion gene in T-cell acute lymphoblastic leukemia. Leukemia, 2009, 23, 125-133.	7.2	65
76	JAK1 mutation analysis in T-cell acute lymphoblastic leukemia cell lines. Haematologica, 2009, 94, 435-437.	3.5	11
77	The HOX11/TLX1 Transcription Factor Oncogene Induces Chromosomal Aneuploidy in T-ALL.. Blood, 2009, 114, 142-142.	1.4	8
78	Deletion of the Protein Tyrosine Phosphatase Gene PTPN2 in T-Cell Acute Lymphoblastic Leukemia.. Blood, 2009, 114, 141-141.	1.4	0
79	Oncogenic Transcriptional Programs Controlled by TLX1/HOX11 and TLX3/HOX11L2 in T-ALL.. Blood, 2009, 114, 676-676.	1.4	0
80	Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases. Leukemia, 2008, 22, 2208-2216.	7.2	42
81	Kinase Activation and Transformation by NUP214-ABL1 Is Dependent on the Context of the Nuclear Pore. Molecular Cell, 2008, 31, 134-142.	9.7	55
82	In vitro validation of Â-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia. Haematologica, 2008, 93, 533-542.	3.5	77
83	ABL1 fusions in T-cell acute lymphoblastic leukemia. Verhandelingen - Koninklijke Academie Voor Geneeskunde Van BelgiÃ«, 2008, 70, 245-55.	0.2	2
84	Impact of weak Fermi-level pinning on the correct interpretation of III-V MOS C-V and G-V characteristics. Microelectronic Engineering, 2007, 84, 2146-2149.	2.4	55
85	Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. Nature Genetics, 2007, 39, 593-595.	21.4	252
86	Clinical, cytogenetic and molecular characteristics of 14 T-ALL patients carrying the TCRÎ²-HOXA rearrangement: a study of the Groupe Francophone de CytogÃ©nÃ©tique HÃ©matologique. Leukemia, 2007, 21, 121-128.	7.2	43
87	Chronic myeloproliferative disorders: a tyrosine kinase tale. Leukemia, 2006, 20, 200-205.	7.2	63
88	Transition from EML1-ABL1 to NUP214-ABL1 positivity in a patient with acute T-lymphoblastic leukemia. Leukemia, 2006, 20, 2202-2204.	7.2	10
89	Array-CGH Analysis of T-ALL Patients and Cell Lines.. Blood, 2006, 108, 4469-4469.	1.4	0
90	Oncogenic Properties of the T-ALL Associated EML1-ABL1 and NUP214-ABL1 Fusion Proteins.. Blood, 2006, 108, 1830-1830.	1.4	5

#	Article	IF	Citations
91	Involvement of the NOTCH1 and NOTCH2 Genes in B-Cell Lymphomagenesis.. Blood, 2006, 108, 2072-2072.	1.4	8
92	Development of a Myeloproliferative Disease or a T Cell Lymphoblastic Leukemia in a Murine Bone Marrow Transplant Model of NUP214-ABL1.. Blood, 2006, 108, 618-618.	1.4	10
93	Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32). Blood, 2005, 105, 4849-4852.	1.4	119
94	Genetic insights in the pathogenesis of T-cell acute lymphoblastic leukemia. Haematologica, 2005, 90, 1116-27.	3.5	84